Bowie E A, Hurley P J
Aust N Z J Med. 1975 Aug;5(4):306-14. doi: 10.1111/j.1445-5994.1975.tb03263.x.
The effect of oral cobalt chloride on the anaemia of patients undergoing long-term haemodialysis therapy was investigated in 14 patients taking 25 mg then 50 mg daily. After eight weeks of treatment the mean haematocrit increase in 11 patients completing the trial was 23% of the original level and the 51Cr-red cell volume had increased by 20%. The 51Cr red half-life lengthened after treatment in six patients and the 59Fe plasma half-time shortened in ten patients. After treatment, evidence of increased erythropoietic activity was seen in the bone marrow of five patients. No evidence was found of thyroid of liver dysfunction but three patients developed transient loss of hearing demonstrated by audiometry. Cobalt chloride appears to be helpful in the management of some uraemic patients with refractory anaemia.
对14例长期接受血液透析治疗的患者进行了研究，这些患者每天服用25毫克然后50毫克口服氯化钴，以观察其对贫血的影响。经过八周的治疗，完成试验的11例患者的平均血细胞比容增加了原始水平的23%，51铬红细胞体积增加了20%。6例患者治疗后51铬红细胞半衰期延长，10例患者59铁血浆半衰期缩短。治疗后，5例患者的骨髓中出现了红细胞生成活性增加的证据。未发现甲状腺或肝功能障碍的证据，但有3例患者通过听力测定显示出现短暂听力丧失。氯化钴似乎有助于治疗一些难治性贫血的尿毒症患者。
